▲ Peaking
Business
Novo outlook hike falls flat as Wegovy pill sales fail to impress
Novo shares fell six percent following second-quarter earnings despite a raised outlook, as Wegovy pill sales disappointed.
Wegovy
19 trends tracked about this subject — the full history, oldest to newest below.
◼ Archived
Health
🔮 fades ✓
As of July 1, Medicare Covers Wegovy for Weight Loss at $50 a Month. The Eligibility List Is Short.
4 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
Some people are getting shut out when it comes to GLP-1 drugs. Here’s why.
Patients are facing restricted access to GLP-1 drugs like Ozempic and Wegovy due to high costs and restrictive insurance policies.
◼ Archived
Health
🔮 fades ✓
Rare eye disorder linked to Ozempic-like medications
Australian regulators and medical reports link GLP-1 weight-loss drugs like Ozempic to a rare and severe risk of permanent vision loss.
◼ Archived
Health
🔮 holds
Georgia woman part of lawsuit claiming link between GLP-1 weight loss drugs and blindness - WSB-TV
A Georgia woman has joined a growing lawsuit connecting popular GLP-1 weight loss drugs to a rare and blinding eye condition.
◼ Archived
Health
🔮 fades
Does stopping a GLP-1 really doom you to regain all the weight?
Recent medical reviews suggest users of GLP-1 weight-loss medications may face significant weight regain after stopping treatment.
◼ Archived
Health
🔮 fades
She Used Weight-Loss Drugs From a Telehealth Company, Then a GLP-1 Overdose Sent Her to the ER
A 54-year-old woman's emergency room hospitalization after a GLP-1 overdose highlights rising public safety concerns.
◼ Archived
Business
🔮 fades
11% of Americans Are Currently Taking a GLP-1 Weight Loss Drug Like Wegovy
Recent data indicates that 11% of the American population is now utilizing GLP-1 weight loss medications such as Wegovy.
◼ Archived
Health
🔮 fades
Wegovy weight loss pill now available in UK
Wegovy weight‑loss pill hits UK shelves today, sparking a predicted rush of tens of thousands of users.
◼ Archived
Business
🔮 fades
Medicare is about to cover GLP-1 drugs for weight loss. Here’s what to know.
Medicare initiates a pilot program providing coverage for GLP-1 weight-loss medications beginning July 1, 2026.
◼ Archived
Health
🔮 fades
When Diets Don’t Work: Parents Turn to Wegovy for Elementary School Kids
Parents are increasingly administering weight-loss medications like Wegovy to elementary school children as young as six to combat obesity.
◼ Archived
Health
🔮 fades
Ozempic and Wegovy may strengthen bones in Type 2 diabetes patients, study finds
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
🔮 fades
Taking A Break? Study Finds Why Many GLP-1 Users Stop And Restart Their Medication
6 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
🔮 fades
Ozempic and Wegovy linked to drop in violent behavior, study finds
2 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
🔮 holds
Scientists Find Intriguing Link Between Ozempic and Violent Behavior
16 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
🔮 fades
The latest benefit of obesity drugs: boosting testosterone and sperm quality
New research indicates that GLP-1 obesity medications may provide unexpected benefits for male fertility by increasing testosterone and sperm quality.
◼ Archived
Health
🔮 fades
Ozempic Users Are Skimping Out on Exercise, Study Finds
New research indicates that patients taking GLP-1 weight loss drugs are reducing their physical activity levels.
◼ Archived
Health
🔮 holds
The hidden cost of weight-loss drugs: scurvy, anaemia, bleeding gums
GLP-1 weight-loss drugs are exposing a hidden health crisis: nutrient deficiencies linked to rapid weight loss
◼ Archived
Business
🔮 fades
Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases
US employers may halt GLP-1 drug coverage in 2027 amid rising costs and usage spikes